Nasal Delivery Of Psychedelics: Next Generation Delivery Options

Psychedelic programmes are no longer defined mainly by regulatory resistance. The harder questions now sit in formulation: poorly soluble, unstable, highly potent compounds, extremely low occupational exposure limits, and clinical trial designs where placebo comparison breaks down. Dr Richard Johnson, Founding Director and Chief Scientific Officer of Upperton, a UK-based CDMO, weighs these constraints against the demands of therapy that pairs drug administration with guided sessions. A comparison of oral, injectable, and nasal forms against the dosing attributes this approach requires shows why developers of rapid-acting molecules are converging on one route, and what that means for pipelines now in clinical and preclinical stages.

Examine the comparison and the reasoning behind it.